Last reviewed · How we verify
Fimasartan/HCTZ combination
Fimasartan blocks angiotensin II type 1 receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume and further decrease blood pressure.
Fimasartan blocks angiotensin II type 1 receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume and further decrease blood pressure. Used for Hypertension.
At a glance
| Generic name | Fimasartan/HCTZ combination |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker / Thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fimasartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced vasoconstriction. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Headache
Key clinical trials
- Fimasartan in the Senior Subjects (PHASE3)
- Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (PHASE1)
- Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (PHASE1)
- A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide (PHASE2)
- Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension (PHASE3)
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fimasartan/HCTZ combination CI brief — competitive landscape report
- Fimasartan/HCTZ combination updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI